CLBS16
BiologicalGCSF-mobilized autologous CD34 cells
NCT Number: NCT03508609
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS16.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Cedars-Sinai Medical Center, Los Angeles, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GCSF-mobilized autologous CD34 cells
Time frame: Day 180
Coronary Flow Reserve (CFR) is a measure of coronary microvascular function.
Time frame: Day 180
Time frame: Day 180
Time frame: 6 months
Time frame: 6 months
Canadian Cardiovascular Society angina class grading scale is assessed according to the following scores:
Grade 1: Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation Grade 2: Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions Grade 3: Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace Grade 4: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest A higher grade is a worse outcome.
Time frame: 6 months
The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).
Time frame: 6 months
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
Lisata Therapeutics, Inc.
Industry
An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05711719
Coronary Microvascular Dysfunction, Glucose Metabolism Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT06294730
Coronary Microvascular Dysfunction, Endothelial Dysfunction
Stockholm, Sweden
View Trial DetailsNCT05790876
Cardiovascular Diseases, Coronary Microvascular Dysfunction
La Tronche, France
View Trial DetailsNCT06715137
Cardiovascular Abnormalities, Cardiovascular Diseases
Edegem, Antwerp, Belgium
View Trial Details